A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy — DOVE-M

Advanced Malignant Pleural Mesothelioma Clinical Trial

Official title:
A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy

Status Terminated

Clinical Trial Summary

This is a single-arm, open label, two stage, phase II study of dovitinib in patients with advanced Malignant Pleural Mesothelioma (MPM). The primary purpose of this study is to evaluate the potential efficacy of dovitinib in the second- or third-line treatment of MPM using progression free survival (PFS).

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Advanced Malignant Pleural Mesothelioma
Mesothelioma
MPM

Clinical Trial Details

NCT number	NCT01769547
Study type	Interventional
Source	Ontario Clinical Oncology Group (OCOG)
Contact
Status	Terminated
Phase	Phase 2
Start date	March 2013
Completion date	June 2015

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01869023` - Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma	Phase 2
Completed	`NCT01358084` - Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM	Phase 2
Terminated	`NCT04166734` - Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma	Phase 1